Standout Papers

Combining p53 mRNA nanoth... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy
    2022 176 citations Yuling Xiao, Hui Zhou et al. Nature Communications profile →

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 56 hit
Sub-graph 1 of 21

Citing Papers

Activatable Photosensitizers: From Fundamental Principles to Advanced Designs
2025 Hit
Glucose‐Activated Programmed Hydrogel with Self‐Switchable Enzyme‐Like Activity for Infected Diabetic Wound Self‐Adaptive Treatment
2025 Hit
2 intermediate papers

Works of Zhiping Ruan being referenced

Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy
2022 Hit

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Zhiping Ruan 714 402 319 210 167 57 1.2k
Chao Liang 720 1.0× 330 0.8× 345 1.1× 150 0.7× 139 0.8× 53 1.2k
Jing Ma 625 0.9× 387 1.0× 390 1.2× 164 0.8× 92 0.6× 46 1.3k
Zhe Liu 653 0.9× 320 0.8× 327 1.0× 118 0.6× 144 0.9× 52 1.1k
Ke Li 691 1.0× 319 0.8× 218 0.7× 155 0.7× 278 1.7× 48 1.4k
Ryouichi Tsunedomi 665 0.9× 603 1.5× 334 1.0× 157 0.7× 205 1.2× 64 1.3k
Wenjie Zheng 616 0.9× 222 0.6× 354 1.1× 159 0.8× 145 0.9× 64 1.1k
Moo Jun Baek 528 0.7× 491 1.2× 243 0.8× 195 0.9× 174 1.0× 87 1.3k
Chenyue Zhang 676 0.9× 571 1.4× 463 1.5× 299 1.4× 196 1.2× 74 1.4k
Wenjuan Yang 626 0.9× 317 0.8× 301 0.9× 189 0.9× 222 1.3× 99 1.4k
Wen‐Ying Lee 595 0.8× 322 0.8× 335 1.1× 155 0.7× 103 0.6× 56 1.3k

All Works

Loading papers...

Rankless by CCL
2026